Heart Risk Seen With GlaxoSmithKline (GSK)'s Zofran?

6/29/2012 12:37:55 PM

GlaxoSmithKline has made changes in the dosage label for its anti-nausea drug Zofran, U.S. health regulators said.

The U.S. Food and Drug Administration on Friday said interim data from a clinical study showed a 32 mg single dose of Zofran could cause a potential risk of abnormal hearth rhythm.

Read at Reuters

Read at News Release

Read Article at

Related Companies

News Categories

• Reuters

• News Release

• GlaxoSmithKline

• Clinical - Recalls and Warnings

• Clinical - Drug Product News

• Clinical - Drug Product News (World)